Cargando…

New Insights in (Inter)Cellular Mechanisms by Heart Failure with Preserved Ejection Fraction

Recently, a new paradigm for the development of heart failure with preserved ejection fraction (HFpEF) has been proposed, which identifies a systemic pro-inflammatory state induced by comorbidities as the origin of microvascular endothelial cell inflammation and subsequent concentric cardiac remodel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tschöpe, Carsten, Van Linthout, Sophie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2014
Materias:	Epidemiology of Heart Failure (CSP Lam, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221658/ https://www.ncbi.nlm.nih.gov/pubmed/25189801 http://dx.doi.org/10.1007/s11897-014-0219-3

Ejemplares similares

Right Heart Phenotype in Heart Failure With Preserved Ejection Fraction
por: Guazzi, Marco, et al.
Publicado: (2021)

Efficacy of Ranolazine to Improve Diastolic Performance in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis
por: Putri, Desak Ketut Sekar Cempaka, et al.
Publicado: (2023)

Prognostic impacts of changes in left ventricular ejection fraction in heart failure patients with preserved left ventricular ejection fraction
por: Yoshihisa, Akiomi, et al.
Publicado: (2020)

Baseline characteristics of patients with heart failure and preserved ejection fraction at admission with acute heart failure in Saudi Arabia
por: Abohammar, Samah, et al.
Publicado: (2017)

Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis
por: Beale, Anna L, et al.
Publicado: (2019)

Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction
por: Salah, Khibar, et al.
Publicado: (2019)

Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction
por: Son, Mi Kyoung, et al.
Publicado: (2020)

Diastolic index as a short-term prognostic factor in heart failure with preserved ejection fraction
por: Hoshida, Shiro, et al.
Publicado: (2020)

Heart Failure with Preserved Ejection Fraction—a Concise Review
por: Adamczak, Daria M., et al.
Publicado: (2020)

Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic review
por: Zheng, Sean L, et al.
Publicado: (2016)

Mild aortic valve disease and the diastolic pressure–volume relationship in heart failure with preserved ejection fraction
por: Verbrugge, Frederik H, et al.
Publicado: (2021)

Inflammation – Cause or Consequence of Heart Failure or Both?
por: Van Linthout, Sophie, et al.
Publicado: (2017)

Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study
por: Hage, Camilla, et al.
Publicado: (2015)

Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis
por: Zheng, Sean Lee, et al.
Publicado: (2018)

Non-invasive intraventricular pressure differences estimated with cardiac MRI in subjects without heart failure and with heart failure with reduced and preserved ejection fraction
por: Londono-Hoyos, Francisco, et al.
Publicado: (2019)

Development of algorithms for determining heart failure with reduced and preserved ejection fraction using nationwide electronic healthcare records in the UK
por: Sundaram, Varun, et al.
Publicado: (2022)

Medications for specific phenotypes of heart failure with preserved ejection fraction classified by a machine learning-based clustering model
por: Sotomi, Yohei, et al.
Publicado: (2023)

Developing a contemporary community clinic for patients with heart failure with preserved ejection fraction within the current National Health Service model
por: Tran, Patrick, et al.
Publicado: (2022)

Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure
por: Gijsberts, Crystel M, et al.
Publicado: (2016)

Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition
por: Margonato, Davide, et al.
Publicado: (2020)

Rationale and design of the preserved versus reduced ejection fraction biomarker registry and precision medicine database for ambulatory patients with heart failure (PREFER-HF) study
por: Abboud, Andrew, et al.
Publicado: (2021)

Colchicine in patients with heart failure and preserved left ventricular ejection fraction: rationale and design of a prospective, randomised, open-label, crossover clinical trial
por: Shchendrygina, Anastasia, et al.
Publicado: (2023)

Sacubitril/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis
por: Basile, Christian, et al.
Publicado: (2023)

Implantation of a vagus nerve stimulator for patients with heart failure with reduced ejection fraction: An educational video
por: Al Rameni, Dina, et al.
Publicado: (2022)

Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fraction
por: van Essen, Bart J., et al.
Publicado: (2022)

Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
por: Benini, Annachiara, et al.
Publicado: (2022)

Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study
por: Ganesananthan, Sashiananthan, et al.
Publicado: (2020)

Management of patients with heart failure and preserved ejection fraction
por: Jasinska-Piadlo, Alicja, et al.
Publicado: (2023)

Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England
por: Kolovos, Spyros, et al.
Publicado: (2023)

Extracellular cardiac matrix biomarkers in patients with reduced ejection fraction heart failure as predictors of response to cardiac resynchronisation therapy: a systematic review
por: McAloon, Christopher J, et al.
Publicado: (2017)

Prognostic value of left ventricular mitral annular longitudinal displacement obtained by tissue Doppler imaging in patients with heart failure with reduced ejection fraction
por: Sengeløv, Morten, et al.
Publicado: (2021)

Revascularization in ischemic heart failure with reduced left ventricular ejection fraction. The impact of complete revascularization
por: Pyka, Łukasz, et al.
Publicado: (2017)

Ischaemia change with revascularisation versus medical therapy in reduced ejection fraction
por: Mentz, Robert J, et al.
Publicado: (2015)

Heart Failure Treatment by Device
por: Bayés-Genis, Antoni
Publicado: (2020)

Epicardial Fat Expansion in Diabetic and Obese Patients With Heart Failure and Preserved Ejection Fraction—A Specific HFpEF Phenotype
por: Elsanhoury, Ahmed, et al.
Publicado: (2021)

Myocardial Involvement in COVID-19: an Interaction Between Comorbidities and Heart Failure with Preserved Ejection Fraction. A Further Indication of the Role of Inflammation
por: Zaccone, Gregorio, et al.
Publicado: (2021)

Does lateral approach preserve the right ventricular function after HeartMate 3 insertion?
por: Hayashi, Hideyuki, et al.
Publicado: (2023)

Narrative review: the holy grail: update on pharmacotherapy for heart failure with preserved ejection fraction
por: Paz, Pablo Alejandro, et al.
Publicado: (2021)

Comparative cardiovascular outcomes of novel drugs as an addition to conventional triple therapy for heart failure with reduced ejection fraction (HFrEF): a network meta-analysis of randomised controlled trials
por: Suebsaicharoen, Thanakit, et al.
Publicado: (2023)

Interatrial Shunting for Treating Acute and Chronic Left Heart Failure
por: Guimaraes, Leonardo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qqu38qdt4vrlpdm469k999k3lv